Thyroid Cancer - Pipeline Insight, 2024

This “Thyroid Cancer - Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 51+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Thyroid Cancer: Understanding

Thyroid Cancer: Overview

Thyroid cancer originates in the cells of the thyroid gland, which plays a crucial role in regulating various bodily processes through hormone production. Despite its relatively common occurrence, with over 50,000 new cases reported annually in the United States alone, many people are unaware of its prevalence until it touches someone they know. The disease exhibits a notable gender discrepancy, affecting women at a ratio of three to one, and it can manifest across all age groups, albeit being more prevalent after the age of 30, with a marked increase in aggressiveness among individuals aged 55 and above. Consequently, a significant portion of thyroid cancer patients are women over the age of 30.

Typically, thyroid cancer presents with a nodule on the thyroid, which often remains asymptomatic. It's important to note that the vast majority, over 90%, of thyroid nodules are benign, underscoring the importance of diagnostic procedures. The growth of thyroid cancer almost exclusively occurs within these nodules, rather than affecting the entire thyroid gland itself.

Early stages of thyroid cancer may not elicit noticeable symptoms, with the detection of a neck lump during routine physical examinations being one of the most common indicators. However, it's essential to emphasize that the presence of a lump does not automatically signify cancer, as most thyroid nodules are benign. A biopsy remains the definitive diagnostic tool, wherein small tissue samples are extracted and analyzed for cancerous cells.

Treatment approaches for thyroid cancer are contingent upon various factors, including the cancer type, diagnostic results, stage of advancement, and overall health status. While most thyroid cancers exhibit slow growth and limited metastasis, certain types can display rapid proliferation and dissemination, necessitating prompt and tailored interventions.

"Thyroid Cancer - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Thyroid Cancer pipeline landscape is provided which includes the disease overview and Thyroid Cancer treatment guidelines. The assessment part of the report embraces, in depth Thyroid Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Thyroid Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Thyroid Cancer.

Thyroid Cancer Emerging Drugs Chapters

This segment of the Thyroid Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Thyroid Cancer Emerging Drugs

rhTSH: Suzhou Zelgen Biopharmaceuticals

Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the resultant metabolic disturbance, and without the drawbacks associated with the use of bovine TSH. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with thyroid cancer.

Nivolumab: Bristol-Myers Squibb

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with thyroid cancer.

RX208: Suzhou NeuPharma

RX208 is a potential “best-in-class” BRAF V600E inhibitor with a proprietary novel chemical structure that is different from other marketed BRAF inhibitors. It exhibited high bioavailability and excellent anti-tumor efficacy in preclinical studies. Early clinical data demonstrated preliminary efficacy and good safety and tolerability in patients with cancer, warranting further clinical development. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with thyroid cancer.

AIC100: AffyImmune Therapeutics

AffyImmune’s lead product, AIC100, is an affinity-tuned, ICAM-1 targeted, third generation CAR T cell therapy. AIC100’s CAR has an affinity to ICAM-1 similar to the affinity between naturally-occurring T cells and their targets, which is much lower than most CARs used to date and reduces on-target off-tumor toxicities. AIC100 also expresses SSTR2 for real-time monitoring of CAR T cell distribution and activity. Preclinical studies demonstrate that AIC100 induces robust and enduring tumor eradication without toxicity-related relapse or fatality in various solid tumor models. Studies also suggest the potential for combination with anti-PD-1 therapies. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Thyroid Cancer.

Thyroid Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Thyroid Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Thyroid Cancer

There are approx. 50+ key companies which are developing the therapies for Thyroid Cancer. The companies which have their Thyroid Cancer drug candidates in the most advanced stage, i.e. Phase III include, Suzhou Zelgen Biopharmaceuticals.

Phases

DelveInsight’s report covers around 51+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Thyroid Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Thyroid Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Thyroid Cancer drugs.

Thyroid Cancer Report Insights

• Thyroid Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Thyroid Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Thyroid Cancer drugs?
• How many Thyroid Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Thyroid Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Thyroid Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Thyroid Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AffyImmune Therapeutics
• Suzhou Zelgen Biopharmaceuticals
• Bristol-Myers Squibb
• Suzhou NeuPharma
• AstraZeneca
• Verastem Oncology
• Thryv Therapeutics
• Molecular Targeting Technologies
• Chimerix
• Codiak BioSciences
• LeadArtis
• Tyra Biosciences
• Roche
• Sichuan Kelun-Biotech Biopharmaceutical
• Advenchen Laboratories

Key Products

• AIC100
• rhTSH
• Nivolumab
• RX208
• Tremelimumab
• Avutometinib
• THRV-1257
• 177Lu-DOTA-EB-TATE
• Dordaviprone
• exoASO STAT6
• LEAD-472
• Research programme
• Alectinib
• A 400
• AL-2846

This product will be delivered within 4-6 business days.